Y-L. Wu - Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

T. M. Kim, V. Guarneri, V. P. Jye, L. B. Khaw,J. -J. Yang, M. Wislez, C. Huang, L. Chong Kin, J. Mazieres, L. M. Tho, H. Hayashi, N. Nhung,

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S94-S94

引用0浏览0引用

EGRET: First-in-human Study of the Novel Antibodydrug Conjugate AZD9592 Anti-cancer Agents in Advanced Solid Tumours

C. Aggarwal, B. Solomon, A. Spira, E. Massarelli, S. C. M. Lau, X. Le, C. Rolfo, D. Planchard, E. Felip,Y. -L. Wu,M. -J. Ahn, K. Goto,

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S306-S306

引用0浏览0引用

EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/ metastatic NSCLC

P. A. Janne,B-C. Wang,B. C. Cho,J. Zhao, J. Li, M. J. Hochmair, S. Peters, B. Besse,T. Kato,Y-L. Wu, D. Nguyen, J. Lin,

ANNALS OF ONCOLOGY（2023）

引用0浏览0引用

P2.06-07 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

S.-Y.M. Liu, J.-Y. Deng, H.-H. Yan, M.-Y. Yang,C.-R. Xu, M.-Y. Zheng, B. Gan,X.-C. Zhang,H.-Y. Tu,J.-J. Yang,H.-J. Chen,B.-C. Wang,

Journal of Thoracic Oncologyno. 11 (2023): S319-S320

引用0浏览0引用

EP08.01-070 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

J. Zhao, J. Cui, D. Huang, M. Sun, Z. Ma, Q. Chu, Y. Liu,Z. Wang,X. Li,H. Li, J. Zhang, J. Sun,

Journal of Thoracic Oncologyno. 9 (2022): S373-S374

引用1浏览0引用

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

M. Tsuboi,Y-L. Wu,C. Grohe,T. John,M. Majem Tarruella, J. Wang,T. Kato,J.W. Goldman,S-W. Kim,C-J. Yu,H. Vinh Vu,G. Mukhametshina,

Annals of Oncology (2022): S1413-S1414

引用0浏览0引用

356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

M. Tsuboi,Y-L. Wu,J. He,T. John,C. Grohe,M. Majem,J.W. Goldman,K. Laktionov,S-W. Kim,T. Kato,H.V. Vu,C. Akewanlop,

Annals of Oncology（2020）

引用5浏览0引用

LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence

M. Tsuboi,Y-L. Wu,J. He,T. John,C. Grohe,M. Majem,J.W. Goldman,K. Laktionov,S-W. Kim,T. Kato,H.V. Vu,C. Akewanlop,

Annals of Oncology (2020): S1177

引用3浏览0引用

141TiPASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC)

Parneet K. Cheema,Y. Chen,F. De Marinis,Helano C. Freitas,S. Kim,Alvin Milner,Mariano Provencio,J. Rigas,Y-L. Wu

Annals of Oncology（2017）

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn